<DOC>
	<DOCNO>NCT02540486</DOCNO>
	<brief_summary>Evaluating patient type 2 diabetes either start daily basal insulin require increase basal titration order compare LTHome web base tool usual standard practice insulin glargine dose adjustment .</brief_summary>
	<brief_title>Long Acting Insulin Glargine Titration Web Tool ( LTHome ) v Enhanced Usual Therapy Glargine Titration</brief_title>
	<detailed_description>INNOVATE 12 week , parallel , open-label , randomize , multi-center study evaluate use , safety effectiveness web base tool ( LTHome ) vs. enhance usual therapy ( EUT ) glargine titration T2DM patient . The primary objective study compare effectiveness LTHome versus EUT glargine titration people T2DM patient basal insulin meeting local target patient require basal initiation . Success measure percentage subject reach Canadian Diabetes Association ( CDA ) guideline target . The efficacy objective demonstrate percentage ( % ) subject reach FPG target titration insulin glargine use LTHome tool dose adjustment advice inferior % subject reach FPG target use Enhanced Usual Therapy glargine titration study participation ( LTHome vs. EUT treatment ) . The secondary objective study assess safety , effectiveness , satisfaction adherence LTHome use versus Enhanced Usual Therapy glargine titration .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patient type 2 diabetes mellitus ( T2DM ) 18 75 year old ( inclusively ) BMI ≤ 45 kg/m2 . Signed write informed consent Patients schedule : initiate basal insulin treatment increase dose current basal insulin therapy , independently study participation , : • inadequate blood glucose control If basal therapy screening , must use stable dose insulin glargine x 1 week prior randomization Patients poor blood glucose control define : HbA1c level &gt; 7 % screening AND mean FPG &gt; 7 mmol/l determine recent selfmeasured blood glucose 3 7 day prior randomization Patients proficient computer literacy Patient able willing monitor glucose home glucose monitor , consistently record his/her blood glucose insulin dose patient diary/web tool . Any technical/administrative reason make impossible include patient study , include closing enrollment due full enrollment Patient previously participate clinical trial investigate LTHome algorithm Patient withdraws consent screening ( start sign informed consent form ) Use systemic steroid last 90 day Conditions/situations : Patients short life expectancy ( less 1 year ) Type 1 diabetes mellitus Patients conditions/concomitant diseases make nonevaluable primary efficacy endpoint Clinically significant cardiac disease , retinopathy , hepatic , renal dysfunction relevant major disease determine Principal Investigator designee . Unstable oral antihyperglycemic drug and/or GlucagonLike Peptide Receptor ( GLP1R ) Agonists therapy 4 week period prior screen Impossibility meet specific protocol requirement ( e.g . ability perform blood glucose measurement , manage insulin glargine administration deem unlikely safely manage insulin dosage guidance HCP ) Patient primary relative Investigator SubInvestigator , research assistant , pharmacist , study coordinator , staff directly involve conduct protocol Patients hypoglycemia unawareness , severe hypoglycemic episode last 90 day hospitalization ( reason ) last 30 day Cognitive disorder , dementia neurologic disorder , would affect patient 's ability participate study , patient legal capacity guardianship Pregnant breastfeeding woman , woman childbearing potential protect highly effective method ( ) birth control ( define inform consent form and/or local protocol addendum ) unwilling unable tested pregnancy . Patients use , need start use , mealtime ( Bolus ) insulin timeframe study . Night shift worker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>T2DM</keyword>
</DOC>